Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (Nasdaq: ALIM) announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for an IND application to initiate a Phase III clinical study of fluocinolone acetonide intravitreal implant. This study aims to support marketing approval in mainland China for treating diabetic macular edema. The trial is designed to align with Alimera’s existing U.S. indication, targeting patients previously treated with corticosteroids who did not experience significant intraocular pressure increases. Alimera's leadership expresses excitement about this development.
Positive
- Ocumension has received IND approval for a Phase III clinical study in China.
- The study targets diabetic macular edema, aligning with Alimera's existing U.S. indication.
Negative
- None.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was +1.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that its partner, Ocumension Therapeutics (“Ocumension”) received approval from the National Medical Products Administration for its IND application to begin the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.
“We are very excited by the progress that Ocumension is making toward generating the data needed to seek approval in China for our intravitreal implant,” said Rick Eiswirth, President and CEO of Alimera. “We look forward to the start of the trial and to the subsequent data.”
The IND application was for a randomized, multicenter Phase III clinical study of 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the treatment of diabetic macular edema. The intent of the trial is to support a future NDA filing to gain marketing approval in the country with an equivalent indication to Alimera’s U.S. indication (for the treatment of diabetic macular edema previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure).
About Alimera
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com
About Ocumension Therapeutics
Ocumension is an ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. The Group has a portfolio of 23 drug assets, covering all major front- and back-of-the-eye diseases, among which seven key drug candidates are in phase III clinical trial stage.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera scottg@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.